DDInter1348 DDInter833
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Orlistat {u} (Compound) binds {v} (Gene) PNLIP
PNLIP {u} (Gene) is bound by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} (Compound) treats {v} (Disease) obesity
obesity {u} (Disease) is associated with {v} (Gene) PNLIP
PNLIP {u} (Gene) is bound by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomitapide {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ergocalciferol
Ergocalciferol {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat {u} (Compound) resembles {v} (Compound) Sodium Tetradecyl Sulfate
Sodium Tetradecyl Sulfate {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Orlistat (Compound) binds PNLIP (Gene) and PNLIP (Gene) is bound by Glycerol phenylbutyrate (Compound)
Orlistat (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Orlistat (Compound) treats obesity (Disease) and obesity (Disease) is associated with PNLIP (Gene) and PNLIP (Gene) is bound by Glycerol phenylbutyrate (Compound)
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Orlistat may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Orlistat may cause a minor interaction that can limit clinical effects when taken with Ergocalciferol and Ergocalciferol (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Orlistat (Compound) resembles Sodium Tetradecyl Sulfate (Compound) and Sodium Tetradecyl Sulfate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Glycerol phenylbutyrate (Compound)